Multiple Sclerosis and Voiding Symptoms: How to Assess?

Multiple Sclerosis Clinical Trial

Official title:

Multiple Sclerosis and Voiding Symptoms: How to Assess?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04928716
• Other study ID #: GRC 01 GREEN
• Status: Completed
• Start date: January 1, 2019
• Est. completion date: January 1, 2020

Study information

• Verified date: June 2021
• Source: Pierre and Marie Curie University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In multiple Sclerosis (MS), storage and voiding symptoms are well described. Urodynamic patterns underlying storage symptoms are clearly defined, but the assessment of voiding phase in neurological diseases is a sensitive topic. The international continence society (ICS) recommended performing pressure flow studies to assess voiding phase. Assessments of sphincter relaxation and detrusor contractility during voiding phase are tough aims to achieve. Indeed, there is no consensus for the detrusor contractility assessment on women or on patients with neurogenic bladder. Similarly, assessment of sphincter during bladder filling and during the voiding phase is not included in ICS recommendations. In the end, it is the physicians who conclude from the non-formalized urodynamic data if there is a DSD or detrusor underactivity. In MS patients undergoing urodynamics, studies reported 43% DSD and 12% impaired contractility. These data should be interpreted with caution due to the variability of the assessment methods.

This study aims to describe the voiding phase of MS patients with standardized urodynamic evaluation and parameters.

This prospective observational study was conducted in a neuro-urology department of a French university hospital.

All the MS patients consulting for a first urodynamic evaluation without urinary treatment were included. Standardized urodynamic evaluation included an uroflowmetry, urethral pressure profile, two pressure-flow studies. If no detrusor contractility was observed during the pressure flow studies, cystometries with 100ml/min filling rate and ice water test were performed. Anal sphincter activity was recorded using surface electromyography electrodes.

Demographic data (age, sex), disease course of the MS, treatments, Expanded Disability Status Scale, urinary symptoms using the Urinary Symptom Profile and the Neurogenic Bladder Symptom Score were collected.

For assessment of detrusor contractility, the following parameters are reported: the bladder voiding efficiency; the projected isovolumetric pressure (PIP) or bladder contractility index (BCI); the Watts factor. For women, the investigators presented 3 more parameters the PIP1; the Valentini-besson-Nelson parameter k and an urodynamic cut-off proposed by Gammie et al. for DUA. Presence of Detrusor-sphincter dyssynergia was reported if there were a detrusor contraction concurrent with an involuntary contraction of the periurethral striated muscle.

Description:

Lower urinary tract (LUT) dysfunctions are common in multiple sclerosis (MS) with almost all the patients reporting LUT symptoms at 10 years of duration of MS.LUT dysfunctions affect one patient out of ten at the time of the first neurological symptoms and negatively impact patients' quality of life.

In MS, storage and voiding symptoms are well described. Urodynamic patterns underlying storage symptoms are clearly defined, but the assessment of voiding phase in neurological diseases is a sensitive topic. The international continence society (ICS) recommended to perform pressure flow studies to assess voiding phase. In 2018, the ICS defined altered sphincter function and detrusor function during pressure flow studies in neurogenic LUT dysfunction. Three types of sphincter dysfunctions are reported: detrusor-sphincter dyssynergia (DSD) defined as "a detrusor contraction concurrent with an involuntary contraction of the urethral and/or periurethral striated muscle. Occasionally flow may be prevented altogether." , non-relaxing urethral sphincter as "a non-relaxing, obstructing urethral sphincter resulting in reduced urine flow" and delayed relaxation of the urethral sphincter as "an impaired and hindered relaxation of the sphincter during voiding attempt resulting in delay of urine flow". Regarding detrusor dysfunction during voiding phase, two types are reported: Neurogenic detrusor underactivity (DUA) defined as "a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span in the setting of a clinically relevant neurologic disorder", neurogenic acontractile detrusor "is one that cannot be demonstrated to contract during urodynamic studies in the setting of a clinically relevant neurologic lesion". In studies in MS patients undergoing urodynamic testing, this classification was not used. First because these definitions are recent, secondly because assessing sphincter relaxation and detrusor contractility during voiding phase are tough aims to achieve. Indeed, there is no consensus for the detrusor contractility assessment on women or on patients with neurogenic bladder. Similarly, assessment of sphincter during bladder filling and during the voiding phase is not included in ICS recommendations. In the end, it is the physicians who conclude from the non-formalized urodynamic data if there is a DSD or detrusor underactivity. In MS patients undergoing urodynamics, studies reported 43% DSD and 12% impaired contractility. These data should be interpreted with caution due to the variability of the assessment methods.

This study aims to describe the voiding phase of MS patients with standardized urodynamic evaluation and parameters.

This prospective observational study was conducted in a neuro-urology department of a French university hospital.

All the MS patients consulting for a first urodynamic evaluation without urinary treatment were included. Standardized urodynamic evaluation included an uroflowmetry, urethral pressure profile, two pressure-flow studies. If no detrusor contractility was observed during the pressure flow studies, cystometries with 100ml/min filling rate and ice water test were performed in order to identify contractility of the detrusor. Anal sphincter activity was recorded during the urodynamic testing using surface electromyography electrodes. Urodynamic evaluation was realized in accordance with ICS recommendation.

Demographic data (age, sex), disease course of the MS, treatments, Expanded Disability Status Scale (EDSS), urinary symptoms using the Urinary Symptom Profile (USP) and the Neurogenic Bladder Symptom Score (NBSS) were collected.

Detrusor contractility assessment.

For assessment of detrusor contractility on patients with neurological disease, the following parameters are reported: (i) the bladder voiding efficiency (BVE) defined as a percentage (BVE= (voided volume/total bladder capacity) x 100) ; (ii) the projected isovolumetric pressure (PIP) or bladder contractility index (BCI) given by the formula BCI=PdetQmax + 5Qmax with a strong contractility if BCI >150, normal contractility if BCI of 100-150 and weak contractility if BCI <100 ; (iii) the Watts factor (WF) = [(Pdet + a)(vdet + b) - ab]/2π where Pdet is the detrusor pressure, vdet is the velocity of detrusor contraction, and a (25 cmH2O) and b (0.6 cm/s) are back-calculated muscle constants representing the heat of shortening and the rate of energy liberation, respectively.

For women, the investigators presented 3 more parameters (i) the PIP1= PdetQmax + Qmax ; (ii) the Valentini-besson-Nelson (VBN) parameter k (simulating detrusor force) and (iii) an urodynamic cut-off proposed by Gammie et al. for DUA with PdetQmax <20; Qmax <15, and BVE <90%.

The conclusions of the detrusor contractility assessment were reported. This conclusion was made with a double reading of the urodynamic curves: the first assessment was made by the physician who initially received the patient; a second reading of the pressure-flow studies was made in blind by CC.

Bladder outlet obstruction was assessed with the Bladder Obstruction outlet index (BOOI). Presence of Detrusor-sphincter dyssynergia was reported if there were a detrusor contraction concurrent with an involuntary contraction of the periurethral striated muscle.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: January 1, 2020
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Multiple sclerosis (Mc Donalds criterias 2017)

• performing an urodynamic evaluation

Exclusion Criteria:

• patients with urinary treatment

Related Conditions & MeSH terms

• Lower Urinary Tract Symptoms
• Multiple Sclerosis
• Sclerosis
• Voiding Disorders

Intervention

Other:
• voiding phase evaluation
Assessment of voiding phase in multiple sclerosis patients

Locations

Country	Name	City	State
France	Department of Neuro- Urology, Hôpital Tenon	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Pierre and Marie Curie University

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of the voiding phase	assessment of the voiding phase in multiple sclerosis patients with description of the existing parameters in urodynamic tests	1 day